Adding Takeda’s Ninlaro (ixazomib) to Revlimid (lenalidomide) and dexamethasone failed to significantly extend life without disease progression in people newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplant, top-line data from a Phase 3 clinical trial show. Still, Ninlaro’s triple combination was significantly superior to the Revlimid-dexamethasone combo at promoting profound treatment responses, delaying time to progression, and extending progression-free survival in patients with high-risk cytogenetics (chromosomal abnormalities). The findings, “Ixazomib Plus…
You must be logged in to read/download the full post.
The post Ninlaro Combo Fails to Halt Progression of Newly Diagnosed Multiple Myeloma, Trial Data Show appeared first on BioNewsFeeds.